Air France KLM (AF) Quote

Great post. It was much needed. Love your simplistic style of explanation. https://www.your-texasbenefits.com YourTexasBenefits

Want a crystal ball? Continue watching Nikkei. This is how the Nikkei closed earlier, clearly this market doesn’t hold up very well as soon as real sellers show up. No need for further comments
https://pbs.twimg.com/media/GXGA8_obEAEcaET?format=jpg&name=large

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Silexion Therapeutics represents a unique approach in the fight against KRAS-driven cancers, particularly pancreatic cancer. Its innovative RNAi technology, delivered via the LODER™ platform and the promising SIL-204, seems to address many of the challenges that have historically limited progress in

$GSAC sharing my DD based on recent financials: 1/3

✔️ NO dilution recently
✔️ NICE SS - public float 1.2B; more then 50% of OS is held by insiders; market cap 1.2M
✔️ PRODUCTS and SERVICES - technology for the industrial security and renewable energy markets

$GSAC sharing my DD based on recent financials: 1/3

✔️ NO dilution recently
✔️ NICE SS - public float 1.2B; more then 50% of OS is held by insiders; market cap 1.2M
✔️ PRODUCTS and SERVICES - technology for the industrial security and renewable energy markets

$GSAC sharing my DD based on recent financials: 1/3

✔️ NO dilution recently
✔️ NICE SS - public float 1.2B; more then 50% of OS is held by insiders; market cap 1.2M
✔️ PRODUCTS and SERVICES - technology for the industrial security and renewable energy markets

Silexion's LODER™ technology has already shown promising results in Phase 2 clinical trials for locally advanced pancreatic cancer. Key findings include a 9.3-month improvement in overall survival when LODER™ was combined with standard chemotherapy, compared to chemotherapy alone in patients with no

Technology Deep Dive: LODER™ and SIL-204

At the core of Silexion's approach is its proprietary LODER™ (Local Drug EluteR) platform, which has demonstrated encouraging results in Phase 2 clinical trials for locally advanced pancreatic cancer. The company's technology stands out due to

Experts don't bash. We succeed. NWPN is a piece of paper in a cabinet and some PDF's. JUST LIKE ALL .0001 stocks.

To believe otherwise is naive. To "invest" is ignorant.
Buy NWPN I'm all for it but don't push the new CEO narrative like this is Kellogg.

Buy bund

Will shorty try to drive it down under 3 today? I’m nervous

😂😂😂,, people are different everywhere. That’s the fun in seeing new places.. Try to make the best of it. Are there any nice golf courses ??? 😂😂😂😂😂😂

Buy under .002, flip at .0022 or so, Ive done several times. Its the Sharp ATM for $200 a pop lol

Just in case - fasten your seatbelts

Traders are so sure about the incoming FED rate cut next week that T-Bills are now fully pricing it. However if the BLS “political support” for the current US administration is fading and, like it did with the NFP last week (post below), the BLS d

Covid flue season blooming still holding a few here but inclined to add some more ..

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s

$2.5 million note...

... $43 in the bank.

First off, do shareholders not wanna know where those $$$$ went? Slippery JT, but I digress. 🤣

WFD Capital is sweating this one out big-time.

Cannot begin dumping shares until Nov 30th. Whic

Yellen has $700 billion in TGA to pump markets up into rate cuts. So more inclined to SVIX but play a few day trades either side until SVIX confirms a ride back to $30

https://pbs.twimg.com/media/GXGaroRa8AAsC-b?format=jpg&name=large

https://pbs.twimg.com/media/GXGrGS4bEAA-a-d?format=jpg&name=medium